Cosmo Pharmaceuticals NV
SIX:COPN
Cosmo Pharmaceuticals NV
SIX:COPN
Price:
117
CHF
0.69%
Market Closed
Market Cap:
CHf2.1B
Balance Sheet
Balance Sheet Decomposition
Cosmo Pharmaceuticals NV
Cosmo Pharmaceuticals NV
Balance Sheet Decomposition is not available for
Cosmo Pharmaceuticals NV
Cosmo Pharmaceuticals NV
Balance Sheet
Cosmo Pharmaceuticals NV
Cosmo Pharmaceuticals NV
Currency: EUR
| Dec-2006 | Dec-2007 | Dec-2008 | Dec-2009 | Dec-2010 | Dec-2011 | Dec-2012 | Dec-2013 | Dec-2014 | Dec-2015 | Dec-2016 | Dec-2017 | Dec-2018 | Dec-2019 | Dec-2020 | Dec-2021 | Dec-2022 | Dec-2023 | Dec-2024 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Assets | ||||||||||||||||||||
| Cash & Cash Equivalents |
2
|
26
|
22
|
17
|
28
|
14
|
27
|
46
|
34
|
71
|
118
|
145
|
211
|
110
|
186
|
199
|
186
|
50
|
44
|
|
| Cash |
0
|
0
|
0
|
0
|
0
|
0
|
27
|
46
|
34
|
71
|
118
|
145
|
211
|
110
|
186
|
199
|
186
|
50
|
44
|
|
| Cash Equivalents |
2
|
26
|
22
|
17
|
28
|
14
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Short-Term Investments |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
122
|
25
|
45
|
49
|
28
|
139
|
158
|
27
|
24
|
55
|
0
|
99
|
|
| Total Receivables |
8
|
7
|
10
|
9
|
11
|
10
|
9
|
17
|
8
|
19
|
18
|
20
|
19
|
26
|
32
|
39
|
51
|
34
|
31
|
|
| Accounts Receivables |
3
|
3
|
4
|
6
|
6
|
7
|
6
|
12
|
5
|
17
|
15
|
13
|
13
|
19
|
27
|
24
|
39
|
28
|
19
|
|
| Other Receivables |
5
|
3
|
7
|
3
|
5
|
4
|
3
|
6
|
3
|
2
|
3
|
7
|
6
|
7
|
5
|
14
|
12
|
6
|
12
|
|
| Inventory |
1
|
2
|
2
|
2
|
1
|
2
|
2
|
3
|
3
|
2
|
2
|
3
|
4
|
6
|
6
|
13
|
11
|
14
|
14
|
|
| Other Current Assets |
0
|
0
|
0
|
2
|
3
|
3
|
1
|
0
|
0
|
0
|
1
|
2
|
2
|
2
|
3
|
2
|
3
|
3
|
15
|
|
| Total Current Assets |
12
|
34
|
34
|
30
|
43
|
29
|
40
|
188
|
71
|
138
|
187
|
197
|
374
|
302
|
253
|
276
|
306
|
102
|
202
|
|
| PP&E Net |
7
|
3
|
2
|
0
|
2
|
4
|
22
|
22
|
21
|
21
|
21
|
30
|
29
|
30
|
29
|
30
|
30
|
29
|
29
|
|
| PP&E Gross |
7
|
3
|
2
|
0
|
2
|
4
|
22
|
22
|
21
|
21
|
21
|
30
|
29
|
30
|
29
|
30
|
30
|
29
|
29
|
|
| Accumulated Depreciation |
3
|
8
|
11
|
14
|
16
|
20
|
15
|
17
|
19
|
22
|
24
|
26
|
30
|
34
|
37
|
41
|
46
|
51
|
54
|
|
| Intangible Assets |
3
|
6
|
14
|
24
|
41
|
44
|
22
|
16
|
10
|
4
|
20
|
29
|
36
|
49
|
27
|
373
|
366
|
338
|
332
|
|
| Goodwill |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
1
|
1
|
1
|
24
|
24
|
24
|
24
|
|
| Note Receivable |
2
|
2
|
2
|
2
|
2
|
2
|
0
|
0
|
0
|
0
|
0
|
2
|
2
|
12
|
27
|
35
|
10
|
10
|
9
|
|
| Long-Term Investments |
0
|
0
|
7
|
19
|
18
|
18
|
66
|
16
|
121
|
272
|
213
|
230
|
172
|
179
|
251
|
49
|
8
|
3
|
32
|
|
| Other Long-Term Assets |
1
|
2
|
0
|
4
|
11
|
11
|
1
|
1
|
2
|
2
|
3
|
10
|
12
|
10
|
8
|
19
|
15
|
20
|
19
|
|
| Other Assets |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
1
|
1
|
1
|
24
|
24
|
24
|
24
|
|
| Total Assets |
25
N/A
|
47
+87%
|
58
+22%
|
72
+24%
|
92
+28%
|
78
-15%
|
152
+95%
|
243
+60%
|
226
-7%
|
438
+94%
|
443
+1%
|
498
+12%
|
626
+26%
|
585
-6%
|
596
+2%
|
806
+35%
|
760
-6%
|
526
-31%
|
647
+23%
|
|
| Liabilities | ||||||||||||||||||||
| Accounts Payable |
5
|
4
|
4
|
4
|
6
|
4
|
4
|
4
|
5
|
4
|
6
|
11
|
9
|
8
|
8
|
8
|
8
|
9
|
9
|
|
| Accrued Liabilities |
0
|
0
|
0
|
1
|
1
|
4
|
0
|
0
|
0
|
0
|
1
|
1
|
1
|
1
|
1
|
6
|
6
|
7
|
4
|
|
| Short-Term Debt |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Current Portion of Long-Term Debt |
6
|
2
|
1
|
1
|
1
|
1
|
2
|
2
|
2
|
2
|
1
|
1
|
1
|
2
|
3
|
1
|
172
|
1
|
1
|
|
| Other Current Liabilities |
3
|
1
|
4
|
1
|
20
|
1
|
7
|
3
|
53
|
19
|
11
|
6
|
5
|
5
|
10
|
6
|
9
|
9
|
34
|
|
| Total Current Liabilities |
14
|
7
|
9
|
7
|
27
|
10
|
12
|
10
|
61
|
25
|
19
|
19
|
15
|
16
|
22
|
21
|
195
|
25
|
48
|
|
| Long-Term Debt |
5
|
4
|
3
|
2
|
2
|
1
|
11
|
10
|
9
|
7
|
4
|
4
|
158
|
163
|
165
|
169
|
2
|
1
|
1
|
|
| Deferred Income Tax |
1
|
1
|
2
|
2
|
4
|
3
|
3
|
3
|
3
|
2
|
4
|
4
|
7
|
9
|
6
|
100
|
97
|
93
|
91
|
|
| Minority Interest |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
1
|
0
|
0
|
7
|
7
|
7
|
7
|
|
| Other Liabilities |
1
|
1
|
1
|
1
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
4
|
3
|
3
|
2
|
4
|
1
|
|
| Total Liabilities |
21
N/A
|
12
-41%
|
15
+20%
|
12
-19%
|
34
+189%
|
15
-56%
|
28
+86%
|
23
-17%
|
73
+220%
|
34
-53%
|
28
-19%
|
28
0%
|
182
+553%
|
191
+5%
|
196
+2%
|
300
+53%
|
303
+1%
|
129
-57%
|
148
+15%
|
|
| Equity | ||||||||||||||||||||
| Common Stock |
2
|
4
|
4
|
4
|
4
|
4
|
4
|
4
|
4
|
4
|
4
|
4
|
4
|
4
|
4
|
5
|
5
|
5
|
5
|
|
| Retained Earnings |
3
|
32
|
42
|
47
|
51
|
77
|
86
|
156
|
179
|
431
|
437
|
377
|
367
|
346
|
348
|
372
|
341
|
305
|
408
|
|
| Additional Paid In Capital |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
84
|
84
|
84
|
84
|
244
|
244
|
244
|
244
|
|
| Unrealized Security Profit/Loss |
0
|
0
|
2
|
11
|
6
|
7
|
52
|
63
|
63
|
3
|
3
|
4
|
0
|
4
|
6
|
57
|
50
|
55
|
54
|
|
| Treasury Stock |
0
|
0
|
0
|
1
|
2
|
24
|
17
|
2
|
2
|
28
|
28
|
0
|
18
|
44
|
49
|
66
|
90
|
101
|
104
|
|
| Other Equity |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
1
|
7
|
7
|
8
|
8
|
8
|
1
|
1
|
|
| Total Equity |
5
N/A
|
35
+647%
|
43
+23%
|
60
+38%
|
58
-3%
|
63
+9%
|
124
+97%
|
220
+77%
|
152
-31%
|
404
+165%
|
416
+3%
|
470
+13%
|
444
-6%
|
394
-11%
|
400
+2%
|
505
+26%
|
457
-10%
|
397
-13%
|
498
+26%
|
|
| Total Liabilities & Equity |
25
N/A
|
47
+87%
|
58
+22%
|
72
+24%
|
92
+28%
|
78
-15%
|
152
+95%
|
243
+60%
|
226
-7%
|
438
+94%
|
443
+1%
|
498
+12%
|
626
+26%
|
585
-6%
|
596
+2%
|
806
+35%
|
760
-6%
|
526
-31%
|
647
+23%
|
|
| Shares Outstanding | ||||||||||||||||||||
| Common Shares Outstanding |
9
|
14
|
14
|
14
|
15
|
14
|
14
|
15
|
14
|
14
|
14
|
15
|
15
|
15
|
14
|
17
|
16
|
16
|
16
|
|
Switch to:
Switch to:
See Also
Discover More
